Glaxo's Ceftin
Executive Summary
Request for two year patent extension, to 2000, denied. Patent and Trademark's Office said the product is not eligible for extension because Ceftin (cefuroxime axetil) is a salt or ester of cefuroxime, and the sodium salt of cefuroxime was the subject of previous NDAs -- Glaxo's Zinacef and Lilly's Kefurox.